Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2010

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphoma

John Radford
  • Fonction : Auteur
  • PersonId : 889103
Thomas Relander
  • Fonction : Auteur
  • PersonId : 889104
Mats Jerkeman
  • Fonction : Auteur
  • PersonId : 879629
Herve Tilly
  • Fonction : Auteur
  • PersonId : 889105
Anders Osterborg
  • Fonction : Auteur
  • PersonId : 889106
Franck Morschhauser
  • Fonction : Auteur
  • PersonId : 889107
Martin Dreyling
Bo Bang
  • Fonction : Auteur
  • PersonId : 889110

Résumé

Purpose To explore efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T cell lymphoma (PTCL). Patients and Methods Twenty-one adult patients with relapsed or refractory CD4+ PTCL of non-cutaneous type (angioimmunoblastic T-cell lymphoma (AITL) n=9, PTCL-not otherwise specified (NOS) n=7, anaplastic large cell lymphoma (ALCL) n=4 and enteropathy type T-cell lymphoma n=1) were treated in a single-arm multi-center study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26-85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV). Results Objective tumor responses were obtained in 24% of the patients with 2 complete responses unconfirmed (CRu) and 3 partial responses (PR). One of the CRus lasted more than 252 days. Responses were obtained in different PTCL entities: AITL (n=3), ALCL (n=1) and PTCL-NOS (n=1). In general, the trial drug was well tolerated with no major toxicity. No infections related to the trial drug were reported. Conclusion Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.

Mots clés

Fichier principal
Vignette du fichier
PEER_stage2_10.1111%2Fj.1365-2141.2010.08298.x.pdf (309.79 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-00555623 , version 1 (14-01-2011)

Identifiants

Citer

Francesco d'Amore, John Radford, Thomas Relander, Mats Jerkeman, Herve Tilly, et al.. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphoma. British Journal of Haematology, 2010, 150 (5), pp.565. ⟨10.1111/j.1365-2141.2010.08298.x⟩. ⟨hal-00555623⟩

Collections

PEER UNIV-LILLE
160 Consultations
313 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More